Dr. Lal Pathlabs Ltd.

NSE: LALPATHLAB | BSE: 539524 | ISIN: INE600L01024 | Industry: Healthcare Services
| Mid-range Performer
2971.6000 -13.50 (-0.45%)
NSE Jun 12, 2025 15:43 PM
Volume: 165.1K
 

2971.60
-0.45%
Prabhudas Lilladhar
We remain negative on the entire diagnostic chain with a belief of 1) premium players losing their market share to unorganized players, 2) B2B (40% of revenue) partners negotiating to partially offset their loss of profit, 3) Inability to hike prices causing lower realization level (Revenue/Patient) and 4) higher fixed costs (60-65% of operating cost for DLPL), new compliance expense and home collection of samples will lead to lower EBITDA margin. However even after increased estimate, we maintain SELL' recommendation but revised TP to Rs1,006 (from Rs895) on PE 40x of FY22E due to challenging...
Dr. Lal Pathlabs Ltd. is trading above all available SMAs
More from Dr. Lal Pathlabs Ltd.
Recommended